DNA methylation patterns in luminal breast cancers differ from non‐luminal subtypes and can identify relapse risk independent of other clinical variables
Authors:
- Sitharthan KamalakaranSKSitharthan Kamalakaran
- Vinay VaradanVVVinay Varadan
- Hege E. Giercksky RussnesHRHege E. Giercksky Russnes
- Dan LevyDLDan Levy
- Jude KendallJKJude Kendall
- Angel JanevskiAJAngel Janevski
- Michael RiggsMRMichael Riggs
- Nilanjana BanerjeeNBNilanjana Banerjee
- Ellen SchlichtingESEllen Schlichting
- Rolf KåresenRKRolf Kåresen
- K. Shama PrasadaKPK. Shama Prasada
- 2 December 2010
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 5 (1) , 77-92
Abstract
The diversity of breast cancers reflects variations in underlying biology and affects the clinical implications for patients. Gene expression studies have identified five major subtypes– Luminal A, Luminal B, basal‐like, ErbB2+ and Normal‐Like. We set out to determine the role of DNA methylation in subtypes by performing genome‐wide scans of CpG methylation in breast cancer samples with known expression‐based subtypes. Unsupervised hierarchical clustering using a set of most varying loci clustered the tumors into a Luminal A majority (82%) cluster, Basal‐like/ErbB2+ majority (86%) cluster and a non‐specific cluster with samples that were also inconclusive in their expression‐based subtype correlations. Contributing methylation loci were both gene associated loci (30%) and non‐gene associated (70%), suggesting subtype dependant genome‐wide alterations in the methylation landscape. The methylation patterns of significant differentially methylated genes in luminal A tumors are similar to those identified in CD24 + luminal epithelial cells and the patterns in basal‐like tumors similar to CD44 + breast progenitor cells. CpG islands in the HOXA cluster and other homeobox (IRX2, DLX2, NKX2‐2) genes were significantly more methylated in Luminal A tumors. A significant number of genes (2853, p < 0.05) exhibited expression–methylation correlation, implying possible functional effects of methylation on gene expression. Furthermore, analysis of these tumors by using follow‐up survival data identified differential methylation of islands proximal to genes involved in Cell Cycle and Proliferation (Ki‐67, UBE2C, KIF2C, HDAC4), angiogenesis (VEGF, BTG1, KLF5), cell fate commitment (SPRY1, OLIG2, LHX2 and LHX5) as having prognostic value independent of subtypes and other clinical factors.Keywords
This publication has 37 references indexed in Scilit:
- DNA Methylome of Familial Breast Cancer Identifies Distinct Profiles Defined by Mutation StatusThe American Journal of Human Genetics, 2010
- Validation of UBE2C protein as a prognostic marker in node-positive breast cancerBritish Journal of Cancer, 2009
- Cell type-specific DNA methylation patterns in the human breastProceedings of the National Academy of Sciences, 2008
- Topoisomerase levels determine chemotherapy response in vitro and in vivoProceedings of the National Academy of Sciences, 2008
- Endogenous human microRNAs that suppress breast cancer metastasisNature, 2008
- Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 2007
- Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancerMolecular Oncology, 2007
- ASPP: a new family of oncogenes and tumour suppressor genesBritish Journal of Cancer, 2007
- The Spemann organizer gene, Goosecoid , promotes tumor metastasisProceedings of the National Academy of Sciences, 2006
- Repeated observation of breast tumor subtypes in independent gene expression data setsProceedings of the National Academy of Sciences, 2003